...
首页> 外文期刊>Diabetes, metabolic syndrome and obesity: targets and therapy >Mediterranean Diet and Naltrexone/Bupropion Treatment for Weight Loss in Overweight and Obese Breast Cancer Survivors and Non-Cancer Participants: A Pilot Randomized Controlled Trial
【24h】

Mediterranean Diet and Naltrexone/Bupropion Treatment for Weight Loss in Overweight and Obese Breast Cancer Survivors and Non-Cancer Participants: A Pilot Randomized Controlled Trial

机译:地中海饮食和NALTrexone / Bupropion治疗超重和肥胖乳腺癌幸存者和非癌症参与者的减肥:试点随机对照试验

获取原文

摘要

Introduction: The objective of this pilot randomized controlled trial was to investigate the combined effect of a Mediterranean diet and naltrexone/bupropion treatment on body weight, metabolic parameters, and quality of life in overweight or obese breast cancer survivors. Methods: Forty-four breast cancer survivors were randomly assigned to receive the Mediterranean diet plus naltrexone/bupropion medication (breast cancer survivor MeDiet NB group) or the Mediterranean diet alone (breast cancer survivor MeDiet-only group). Twenty-eight age-matched non-cancer patients were instructed to consume the Mediterranean diet plus naltrexone/bupropion medication (non-cancer MeDiet NB group). After the 8-week intervention, changes in body weight, metabolic parameters, nutrient intake, and quality of life of the three groups were assessed. Results: Significant weight loss of 2.8 kg was noted for the breast cancer survivor MeDiet NB group, 1.8 kg for the breast cancer survivor MeDiet-only group, and 2.5 kg for the non-cancer MeDiet NB group after 8 weeks ( P 0.05 versus baseline by Wilcoxon’s signed-rank test). All three groups also exhibited significantly lower fasting glucose, insulin, and homeostasis model assessment of insulin resistance levels ( P 0.05). Quality of life as assessed by self-reported questionnaires showed improvement in all participants ( P 0.05). However, there were no significant differences of changes in body weights, metabolic parameters, and quality of life among the three groups or between the MeDiet NB and MeDiet-only groups. Conclusion: We found that the Mediterranean diet, with or without naltrexone/bupropion treatment, facilitates weight loss, improves metabolic parameters, and increases quality of life. The combination of the Mediterranean diet with naltrexone/bupropion treatment did not produce superior changes when compared to the Mediterranean diet alone. Trial Registration: This trial was retrospectively registered on 10 July 2018 as NCT03581630 at ClinicalTrials.gov ( https://clinicaltrials.gov/ct2/show/NCT03581630 ).
机译:介绍:该试点随机对照试验的目的是探讨地中海饮食和纳曲酮/ Bupropion治疗对体重,代谢参数和超重乳腺癌幸存者中生命质量的综合作用。方法:随机分配44例乳腺癌幸存者,接受地中海饮食加纳纳曲酮/ Bupropion药物(乳腺癌幸存者Mediet NB组)或单独的地中海饮食(乳腺癌幸存者中群)。指示28名与癌症的非癌症患者患者消耗地中海饮食加纳纳曲酮/ Bupropion药物(非癌症Mediet NB组)。评估了8周干预后,评估体重,代谢参数,营养摄入和三组生命质量的变化。结果:乳腺癌幸存者Mediet NB组,1.8公斤乳腺癌幸存者中的乳腺癌中,1.8公斤的重量损失为2.8千克,8周后非癌症中NB组2.5公斤(P <0.05与Wilcoxon的签名等级测试基线)。所有三组也显着降低了胰岛素抵抗水平的空腹葡萄糖,胰岛素和稳态模型评估(P <0.05)。通过自我报告的问卷评估的生活质量显示所有参与者的改善(P <0.05)。然而,在三组或MEDIET NB和METEIT-ONLE的群体之间存在体重,代谢参数和生活质量的变化没有显着差异。结论:我们发现,有或没有纳曲酮/安卸治疗的地中海饮食,有利于减肥,提高代谢参数,提高生活质量。与单独的地中海饮食相比,与纳曲酮/ Bupropion治疗的地中海饮食的结合并没有产生优异的变化。审判注册:本试验在2018年7月10日回顾性在ClinicalTrials.gov(https://clinicaltrials.gov/ct2/show/nct03581630)的NCT03581630。

著录项

获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号